Emergency Med

Your Article Summary

CDCs Advisory Committee Gives Thumbs-up to New Antiviral Recs. Agency Gearing Up for Possible H1N1 Vaccine Distribution
American Family Physician, 07/17/09

Mitchell D – Members of the CDC's Advisory Committee on Immunization Practices, or ACIP, approved new antiviral treatment recommendations during the committee's June 24–26 meeting in Atlanta. The recommendations call for use of:

• zanamivir or a combination of oseltamivir and rimantadine (or amantadine if rimantadine is not available) for treatment of seasonal influenza A (H1N1) virus infection; and
• oseltamivir or zanamivir for treatment of seasonal influenza A (H3N2), novel influenza A (H1N1), or influenza B virus infection.

The CDC now estimates that at least 1 million Americans have been infected with the novel H1N1 virus. The CDC estimate was derived from population–based surveys in areas that have reported incidences of influenza–like–illness to be 6 percent or higher. Five vaccine manufacturers are working to develop a vaccine for the novel H1N1 virus. CDC officials told ACIP members during the meeting that the agency is confident that vaccine – possibly as much as 60 million doses – will be available by October.

<< Previous Clinical Differentiation Between Acute Arterial Embolism and...

Next >> An Unreported Side Effect of Risperidone in Children: Sinus...